Budoprutug

布度扑塔单抗

Report date: 2026/05/26 20:00:28

Base Information

Drug NameBudoprutug
Drug Alias NameTNT-119
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicPurpura, Thrombocytopenic, IdiopathicNephrosis, Lipoid +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEliem Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEliem Therapeutics IncUniversity Of Iowa Pharmaceuticals (Uip)Beijing Mabworks Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicPurpura, Thrombocytopenic, IdiopathicNephrosis +[4] 
Inactive IndicationsNephrosis, LipoidGlomerulosclerosis, Focal Segmental

Other Information

ATC CodeN/A
Related LinksN/A